Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew C Hooker

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|July 28, 2021
Pharmacometrics meets statistics-A synergy for modern drug developmentYevgen Ryeznik, Oleksandr Sverdlov, Elin M Svensson, et al.
The AAPS Journal|August 29, 2020
Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic HyperplasiaYassine Kamal Lyauk, Daniël M Jonker, Trine Meldgaard Lund, et al.
Pharmaceutical Research|February 17, 2017
Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical TrialsPyry Välitalo, Merja Kokki, Veli-Pekka Ranta, et al.
The AAPS Journal|July 31, 2020
Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic HyperplasiaYassine Kamal Lyauk, Trine Meldgaard Lund, Andrew C Hooker, et al.
The AAPS Journal|February 25, 2021
Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaYassine Kamal Lyauk, Daniël M Jonker, Andrew C Hooker, et al.
The AAPS Journal|March 29, 2018
Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 21, 2024
Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxiasAlzahra Hamdan, Andrew C Hooker, Xiaomei Chen, et al.
The AAPS Journal|March 9, 2018
Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
Journal of Clinical Pharmacology|May 6, 2011
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporinStefanie Hennig, Joakim Nyberg, Samuel Fanta, et al.
British Journal of Clinical Pharmacology|February 20, 2014
Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studiesJoakim Nyberg, Caroline Bazzoli, Kay Ogungbenro, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
CPT: Pharmacometrics & Systems Pharmacology|July 28, 2021
Pharmacometrics meets statistics-A synergy for modern drug developmentYevgen Ryeznik, Oleksandr Sverdlov, Elin M Svensson, et al.
The AAPS Journal|August 29, 2020
Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic HyperplasiaYassine Kamal Lyauk, Daniël M Jonker, Trine Meldgaard Lund, et al.
Pharmaceutical Research|February 17, 2017
Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical TrialsPyry Välitalo, Merja Kokki, Veli-Pekka Ranta, et al.
The AAPS Journal|July 31, 2020
Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic HyperplasiaYassine Kamal Lyauk, Trine Meldgaard Lund, Andrew C Hooker, et al.
The AAPS Journal|February 25, 2021
Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaYassine Kamal Lyauk, Daniël M Jonker, Andrew C Hooker, et al.
The AAPS Journal|March 29, 2018
Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 21, 2024
Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxiasAlzahra Hamdan, Andrew C Hooker, Xiaomei Chen, et al.
The AAPS Journal|March 9, 2018
Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
Journal of Clinical Pharmacology|May 6, 2011
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporinStefanie Hennig, Joakim Nyberg, Samuel Fanta, et al.
British Journal of Clinical Pharmacology|February 20, 2014
Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studiesJoakim Nyberg, Caroline Bazzoli, Kay Ogungbenro, et al.
Pageof 8